# 2025年11月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 单细胞转录组图谱揭示犬尿酸在胶质母细胞瘤中调节肿瘤免疫微环境的潜在机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41221633](https://pubmed.ncbi.nlm.nih.gov/41221633)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41221633
**DOI：** 10.1002/advs.202507705

### 第一部分 原文与翻译

**英文原标题：** Single-Cell Transcriptome Atlas Reveals the Underlying Mechanism of Kynurenic Acid in the Regulation of Tumor Immune Microenvironment in Glioblastoma.

**英文摘要原文：**
Tryptophan metabolism plays a critical role in glioblastoma (GBM), however, the regulatory functions of kynurenic acid (KYNA) in this context remain poorly understood. Using an in-house clinical cohort, targeted metabolomic analysis revealed significantly downregulated KYNA levels in GBM tissues compared to non-tumor brain tissues. Further investigation demonstrated that KYNA administration markedly reduced tumor burden in an orthotopic GBM mouse model. Through integrated cytometry by time-of-fight (CyTOF), single-cell RNA sequencing (scRNA-seq), proteome, and flow cytometry analyses, this study delineated the alterative tumor immune landscape following KYNA treatment. Specifically, KYNA remodeled the immunosuppressive myeloid compartment within the GBM microenvironment. Additionally, KYNA reversed T cell exhaustion signatures, enhanced cytotoxic function, thereby augmented anti-tumor T cell responses. Notably, the anti-tumor effects of KYNA are abrogated in T cell-deficient mouse models (nude and Rag2-/-), confirming its dependence on adaptive immunity. In summary, this study highlights the therapeutic potential of KYNA in GBM and provides a comprehensive, multi-omics-based understanding of its immunomodulatory mechanisms.

**中文摘要译文：**
色氨酸代谢在胶质母细胞瘤（GBM）中起着关键作用，然而，犬尿酸（KYNA）在此背景下的调节功能仍知之甚少。利用内部临床队列，靶向代谢组学分析显示，与非肿瘤脑组织相比，GBM组织中的KYNA水平显著下调。进一步的研究表明，在原位GBM小鼠模型中，施用KYNA可显著减轻肿瘤负荷。通过整合飞行时间质谱流式细胞术（CyTOF）、单细胞RNA测序（scRNA-seq）、蛋白质组学和流式细胞术分析，本研究描绘了KYNA治疗后肿瘤免疫图景的改变。具体而言，KYNA重塑了GBM微环境中的免疫抑制性髓系细胞区室。此外，KYNA逆转了T细胞耗竭特征，增强了细胞毒性功能，从而增强了抗肿瘤T细胞反应。值得注意的是，在T细胞缺陷小鼠模型（裸鼠和Rag2-/-小鼠）中，KYNA的抗肿瘤作用被消除，证实了其对适应性免疫的依赖性。总之，本研究凸显了KYNA在GBM中的治疗潜力，并为其免疫调节机制提供了基于多组学的全面理解。

### 第二部分 AI 大师评价

该研究旨在探究色氨酸代谢物犬尿酸（KYNA）在胶质母细胞瘤（GBM）肿瘤免疫微环境中的作用及其潜在机制。研究团队创新性地整合了靶向代谢组学、单细胞测序及蛋白质组学等多组学技术，并结合原位小鼠模型进行验证。核心发现表明，GBM中KYNA水平显著降低，而外源性补充KYNA能通过重塑免疫抑制性髓系细胞、逆转T细胞耗竭来增强抗肿瘤免疫反应，从而有效抑制肿瘤生长。这项工作不仅揭示了KYNA作为GBM潜在治疗靶点的新角色，还为理解代谢物如何调控肿瘤免疫提供了全面的机制性见解，具有重要的科研和临床转化价值。

---

## 2. CircZNF79(5)的失调通过调节YBX1稳定性和选择性自噬驱动肝细胞癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41221627](https://pubmed.ncbi.nlm.nih.gov/41221627)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41221627
**DOI：** 10.1002/advs.202510310

### 第一部分 原文与翻译

**英文原标题：** Dysregulation of CircZNF79(5) Modulates YBX1 Stability and Selective Autophagy to Drive Hepatocellular Carcinoma Progression.

**英文摘要原文：**
Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy with limited therapeutic options. Circular RNAs (circRNAs) have emerged as critical regulators in various cancers, including HCC, but their roles in HCC progression remain largely unexplored. Here, the role of circZNF79(5) in HCC progression and its underlying mechanisms is investigated. CircZNF79(5) expression in HCC tissues, cell lines and the serum exosomes is analyzed using qRT-PCR and FISH, and evaluated its effects on cell proliferation, migration, invasion and apoptosis using CCK8, colony formation, EdU, Transwell and Flow cytometry. CircZNF79(5)'s is verified to be upregulated in HCC, and found that it can promote HCC cells proliferation, migration and invasion, while inhibiting the apoptosis. Mechanistically, circZNF79(5) is found to stabilizes the oncogenic protein YBX1 by recruiting BRCC36, a K63 chain deubiquitinating enzyme, thereby preventing YBX1 from p62-mediated selective autophagic degradation via the AMPK/mTOR signaling pathway. In vivo studies using subcutaneous and orthotopic tumor models confirmed that circZNF79(5) knockdown reduced tumor growth and YBX1 expression. The findings reveal a novel mechanism by which circZNF79(5) promotes HCC progression through YBX1 stabilization and selective autophagy regulation, highlighting the circZNF79(5)-YBX1-BRCC36 axis as a potential therapeutic target for HCC.

**中文摘要译文：**
肝细胞癌（HCC）是一种普遍且具有侵袭性的肝脏恶性肿瘤，其治疗选择有限。环状RNA（circRNA）已成为包括肝细胞癌在内的多种癌症中的关键调控因子，但其在肝细胞癌进展中的作用仍有待深入探索。本研究旨在探讨circZNF79(5)在肝细胞癌进展中的作用及其潜在机制。研究采用qRT-PCR和FISH技术分析了circZNF79(5)在肝细胞癌组织、细胞系及血清外泌体中的表达，并利用CCK8、集落形成、EdU、Transwell及流式细胞术等方法评估了其对细胞增殖、迁移、侵袭和凋亡的影响。研究证实circZNF79(5)在肝细胞癌中表达上调，并发现其能促进肝细胞癌细胞的增殖、迁移和侵袭，同时抑制其凋亡。机制上，研究发现circZNF79(5)通过招募K63链去泛素化酶BRCC36来稳定癌蛋白YBX1，从而通过AMPK/mTOR信号通路阻止YBX1被p62介导的选择性自噬降解。利用皮下及原位肿瘤模型进行的体内研究证实，敲低circZNF79(5)可抑制肿瘤生长并降低YBX1的表达。这些发现揭示了circZNF79(5)通过稳定YBX1和调控选择性自噬促进肝细胞癌进展的新机制，凸显了circZNF79(5)-YBX1-BRCC36轴作为肝细胞癌潜在治疗靶点的重要性。

### 第二部分 AI 大师评价

本研究旨在阐明一种新型环状RNA——circZNF79(5)在肝细胞癌（HCC）进展中的作用和分子机制。研究综合运用了分子生物学、细胞生物学及动物模型等技术手段，发现circZNF79(5)在HCC中高表达，并通过招募去泛素化酶BRCC36来稳定癌蛋白YBX1，进而抑制其选择性自噬降解，最终促进肿瘤恶性进展。该研究的创新之处在于揭示了circRNA通过调控蛋白泛素化与选择性自噬相互作用以驱动癌症的新通路，为理解HCC的发病机制提供了新视角，并提示circZNF79(5)-YBX1-BRCC36轴可能成为HCC治疗的潜在新靶点。

---

## 3. MCUB通过抑制PRKN依赖的线粒体自噬降解PD-L1来促进膀胱癌的免疫逃逸

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41221601](https://pubmed.ncbi.nlm.nih.gov/41221601)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41221601
**DOI：** 10.1002/advs.202514764

### 第一部分 原文与翻译

**英文原标题：** MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer.

**英文摘要原文：**
Muscle-invasive bladder cancer (MIBC) poses a severe threat to patient survival due to its high invasiveness and metastatic potential. Although immunotherapy has revolutionized treatment strategies for MIBC, immune evasion remains a major obstacle limiting therapeutic efficacy. In this study, the mitochondrial calcium uniporter regulatory subunit (MCUB) is investigated for its role in immune evasion in MIBC. Bulk RNA-seq, scRNA-seq, and proteomic analyses revealed a progressive upregulation of MCUB from normal to MIBC tissues, and strong positive correlations are uncovered between MCUB expression and both PD-L1/PD-1 signaling and poor outcomes. Spatial transcriptomics and clinical tissue staining confirmed spatial co-localization of MCUB and PD-L1. Functional experiments demonstrated that MCUB stabilized PD-L1 protein by reducing its lysosomal degradation through inhibition of PRKN-dependent mitophagy. Mechanistically, MCUB suppressed mitochondrial calcium uptake to reduce PRKN activation and physically interacted with the PRKN-Arg51 residue to inhibit its function. In vivo, MCUB knockdown led to reduced tumor growth, enhanced CD8⁺ T cell infiltration, and improved response to anti-PD-1 therapy. This study identified the MCUB-PRKN-PD-L1 axis as a novel driver of immune evasion in MIBC and proposed that targeting the MCUB-PRKN interaction may serve as a precise therapeutic strategy to overcome immune resistance with minimal toxicity to normal tissues.

**中文摘要译文：**
肌层浸润性膀胱癌（MIBC）因其高度的侵袭性和转移潜能，对患者的生存构成严重威胁。尽管免疫疗法已革新了MIBC的治疗策略，但免疫逃逸仍是限制其疗效的主要障碍。本研究旨在探究线粒体钙单向转运体调节亚基（MCUB）在MIBC免疫逃逸中的作用。批量RNA测序、单细胞RNA测序和蛋白质组学分析显示，从正常组织到MIBC组织，MCUB的表达进行性上调，并发现MCUB的表达与PD-L1/PD-1信号传导及不良预后均存在强正相关。空间转录组学和临床组织染色证实了MCUB与PD-L1在空间上的共定位。功能性实验表明，MCUB通过抑制PRKN依赖的线粒体自噬，减少了PD-L1的溶酶体降解，从而稳定了其蛋白水平。机制上，MCUB抑制线粒体钙摄取以减少PRKN的活化，并与PRKN的精氨酸51残基发生物理相互作用以抑制其功能。在体内实验中，敲低MCUB可导致肿瘤生长减缓、CD8⁺ T细胞浸润增强，并改善了对PD-1抑制剂治疗的反应。本研究确定了MCUB-PRKN-PD-L1轴是MIBC中免疫逃逸的一个新驱动因素，并提出靶向MCUB-PRKN相互作用可能是一种精准的治疗策略，用以克服免疫抵抗，且对正常组织的毒性最小。

### 第二部分 AI 大师评价

该研究旨在揭示线粒体钙单向转运体调节亚基（MCUB）在肌层浸润性膀胱癌（MIBC）免疫逃逸中的具体作用。研究综合运用多组学分析、空间转录组学及功能实验，关键发现是MCUB通过抑制PRKN介导的线粒体自噬，减少了PD-L1的溶酶体降解，从而稳定其蛋白水平以促进免疫逃逸。这项工作不仅首次阐明了“MCUB-PRKN-PD-L1”这一全新的免疫调控轴，更提出了靶向MCUB-PRKN相互作用作为一种精准治疗策略，为克服膀胱癌的免疫治疗耐药性提供了极具潜力的临床转化方向。

---

## 4. ALDOA介导的代谢重编程是癌症铁死亡敏化的一个可靶向脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41220277](https://pubmed.ncbi.nlm.nih.gov/41220277)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41220277
**DOI：** 10.1002/advs.202511880

### 第一部分 原文与翻译

**英文原标题：** ALDOA-Mediated Metabolic Reprogramming is a Targetable Vulnerability for Ferroptosis Sensitization in Cancer.

**英文摘要原文：**
Ferroptosis presents great potential for cancer therapy, either alone or in combination with classical therapy. However, inducing ferroptosis by targeting canonical ferroptosis suppressors that directly inhibit lipid peroxidation non-selectively induces ferroptosis in both cancerous and normal cells, thereby limiting its therapeutic potential. In this study, it is revealed that aldolase A (ALDOA) reprograms lipid metabolism to resist ferroptosis in cancer cells and identifies ALDOA as a targetable vulnerability for ferroptosis sensitization. Cancer cells with ALDOA suppression exhibit increased susceptibility to ferroptosis-a response less obvious in normal cells. Mechanistically, ALDOA depletion induces significant accumulation of fructose 1,6-bisphosphate in cancer cells, thereby enhancing autophagy-dependent degradation of phospholipid-modifying enzymes. These alterations increase the ratio of phospholipids containing pro-ferroptotic polyunsaturated fatty acids over anti-ferroptotic monounsaturated fatty acids, culminating in heightened ferroptosis sensitivity. Moreover, ALDOA inhibitors selectively promote ferroptosis in cancer cells, both in vitro and in vivo. Collectively, the findings reveal that ALDOA-mediated metabolic reprogramming is a targetable vulnerability for ferroptosis sensitization in cancer.

**中文摘要译文：**
铁死亡在癌症治疗中展现出巨大潜力，无论是单独使用还是与经典疗法联合使用。然而，通过靶向直接抑制脂质过氧化的经典铁死亡抑制因子来诱导铁死亡，会非选择性地在癌细胞和正常细胞中均诱发铁死亡，从而限制了其治疗潜力。本研究揭示，醛缩酶A（ALDOA）通过重编程脂质代谢来抵抗癌细胞的铁死亡，并将ALDOA鉴定为铁死亡敏化的一个可靶向脆弱性。抑制ALDOA的癌细胞对铁死亡的易感性增加——而这种反应在正常细胞中则不那么明显。从机制上讲，ALDOA的耗竭导致癌细胞中果糖1,6-二磷酸的显著积累，从而增强了磷脂修饰酶的自噬依赖性降解。这些改变提高了含有促铁死亡的多不饱和脂肪酸的磷脂与含有抗铁死亡的单不饱和脂肪酸的磷脂之间的比率，最终导致铁死亡敏感性增强。此外，ALDOA抑制剂在体外和体内均能选择性地促进癌细胞的铁死亡。总而言之，这些发现揭示了ALDOA介导的代谢重编程是癌症铁死亡敏化的一个可靶向脆弱性。

### 第二部分 AI 大师评价

本研究旨在阐明醛缩酶A（ALDOA）在癌细胞抵抗铁死亡中的作用，并评估其作为癌症治疗靶点的潜力。研究通过体外与体内实验发现，抑制ALDOA能够选择性地提高癌细胞对铁死亡的敏感性，而对正常细胞影响较小。其创新之处在于揭示了ALDOA通过调控果糖1,6-二磷酸积累和自噬，进而改变细胞膜磷脂成分来抵抗铁死亡的关键机制。这一发现不仅深化了对肿瘤代谢重编程与铁死亡之间联系的理解，也为开发选择性靶向癌细胞的铁死亡增敏剂提供了极具价值的新策略。

---

## 5. 重新定义乳腺癌相关淋巴水肿的诊断阈值

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41220050](https://pubmed.ncbi.nlm.nih.gov/41220050)
**期刊：** Annals of surgery
**PMID：** 41220050
**DOI：** 10.1097/SLA.0000000000006983

### 第一部分 原文与翻译

**英文原标题：** Redefining the Diagnostic Threshold for Breast Cancer-related Lymphedema.

**英文摘要原文：**
OBJECTIVE: To empirically determine a normative, distribution-based threshold for diagnosing breast cancer-related lymphedema (BCRL) and compare its diagnostic accuracy with the conventional 10% interlimb volume difference criterion.

SUMMARY BACKGROUND DATA: BCRL is a common and morbid sequela of breast cancer treatment; however, diagnostic thresholds remain inconsistent and inadequately validated. The widely used threshold of ≥10% interlimb volume difference may miss clinically relevant cases.

METHODS: This prospective cohort study analyzed preoperative bilateral limb measurements in 858 female breast cancer patients undergoing axillary surgery to derive a normative, distribution-based interlimb volume difference threshold. A threshold corresponding to 2 standard deviations (SD) above the mean (7.5%) was identified. Diagnostic performance of this proposed threshold was then compared with the conventional 10% cutoff in a subgroup of 167 patients who underwent axillary lymph node dissection (ALND) with up to 36 months of postoperative follow-up.

RESULTS: Among 858 patients (median [IQR] age, 48 [40-56] years; median BMI, 25.5 [22.3-30.0] kg/m²), preoperative interlimb volume differences were normally distributed (mean, 0.24%; SD, 3.74%), supporting a proposed diagnostic threshold of 7.5%. In the 167 patients who underwent ALND, 72 (43.1%) met the ≥7.5% threshold versus 53 (31.7%) meeting the 10% threshold, yielding 19 additional diagnoses (+11.4%; P<0.001). Of those meeting the 7.5% threshold, 94.4% (68/72) reported symptoms and/or used compression garments.

CONCLUSIONS: A normative, distribution-based threshold of 7.5% interlimb volume difference improves the identification of clinically meaningful BCRL compared with the traditional 10% cutoff. Adopting this empirically validated threshold may enhance early detection, intervention, and patient outcomes.

**中文摘要译文：**
目的：通过经验性研究，确定一个基于正态分布的规范性阈值，用于诊断乳腺癌相关淋巴水肿（BCRL），并将其诊断准确性与传统的10%患健侧肢体体积差异标准进行比较。

背景概要：BCRL是乳腺癌治疗后常见且致残率高的后遗症；然而，其诊断阈值仍不统一且验证不足。广泛使用的≥10%患健侧肢体体积差异阈值可能会漏诊具有临床意义的病例。

方法：本项前瞻性队列研究分析了858名接受腋窝手术的女性乳腺癌患者术前双侧肢体的测量数据，以推导出一个基于正态分布的规范性患健侧肢体体积差异阈值。研究确定了一个对应于均值以上2个标准差（SD）的阈值（7.5%）。随后，在一个接受了腋窝淋巴结清扫术（ALND）并进行了长达36个月术后随访的167名患者亚组中，将此新提出阈值的诊断性能与传统的10%临界值进行了比较。

结果：在858名患者中（中位[IQR]年龄，48[40-56]岁；中位BMI，25.5[22.3-30.0] kg/m²），术前患健侧肢体体积差异呈正态分布（均值，0.24%；标准差，3.74%），这为提出7.5%的诊断阈值提供了支持。在167名接受ALND的患者中，72名（43.1%）达到了≥7.5%的阈值，而达到10%阈值的有53名（31.7%），新标准额外诊断了19例（+11.4%；P<0.001）。在达到7.5%阈值的患者中，94.4%（68/72）报告了症状和/或使用了压力衣。

结论：与传统的10%临界值相比，一个基于正态分布的规范性阈值——7.5%的患健侧肢体体积差异，能更好地识别出具有临床意义的BCRL。采用这一经过经验验证的阈值可能会促进早期发现、早期干预并改善患者预后。

### 第二部分 AI 大师评价

本研究通过一项大规模前瞻性队列研究，挑战了沿用已久的乳腺癌相关淋巴水肿（BCRL）诊断标准。研究创新性地运用统计学方法，基于正常人群的肢体体积差异分布，提出了一个更低的诊断阈值（7.5%）。关键发现表明，新阈值能比传统10%标准多识别超过11%的临床相关病例，且这些病例多数已有临床症状，证实了其临床意义。该研究成果对BCRL的早期诊断和及时干预具有重大价值，可能推动临床实践指南的更新，从而改善患者的长期生活质量。

---

## 6. 癌症中的三级淋巴结构：时空异质性、免疫调控与转化机遇

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219991](https://pubmed.ncbi.nlm.nih.gov/41219991)
**期刊：** Journal of hematology & oncology
**PMID：** 41219991
**DOI：** 10.1186/s13045-025-01754-7

### 第一部分 原文与翻译

**英文原标题：** Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities.

**英文摘要原文：**
Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that form in or in close proximity to tumors and other chronically inflamed tissues, where they serve as crucial sites for local antigen presentation, lymphocyte priming, and adaptive immune coordination. Increasing evidence across diverse cancers supports TLSs as key modulators of antitumor immunity, correlating with improved patient prognosis and response to immune checkpoint blockade. Yet, TLSs exhibit striking spatiotemporal and functional heterogeneity-ranging from immune-stimulatory to immune-suppressive-which complicates their clinical interpretation and therapeutic targeting. Recent studies have focused on elucidating the molecular cues driving TLS induction, the mechanisms regulating their maturation, and their dynamic interactions with the tumor microenvironment. In this review, we provide an integrated overview of these advances and discuss the clinical and translational implications of TLSs as prognostic biomarkers and immunotherapeutic targets.

**中文摘要译文：**
三级淋巴结构（TLSs）是在肿瘤或其邻近组织以及其他慢性炎症组织中形成的异位淋巴聚集体，是局部抗原呈递、淋巴细胞启动和适应性免疫协调的关键场所。越来越多来自多种癌症的证据表明，TLSs是抗肿瘤免疫的关键调节因子，并与改善的患者预后及对免疫检查点阻断的反应相关。然而，TLSs表现出显著的时空和功能异质性——从免疫刺激性到免疫抑制性不等——这使其临床解读和治疗靶向变得复杂。近期的研究致力于阐明驱动TLS诱导的分子线索、调控其成熟的机制，以及它们与肿瘤微环境的动态相互作用。在这篇综述中，我们对这些进展进行了综合性概述，并探讨了TLSs作为预后生物标志物和免疫治疗靶点的临床与转化意义。

### 第二部分 AI 大师评价

该综述全面概述了三级淋巴结构（TLSs）在肿瘤免疫中的复杂作用。文章系统性地探讨了TLSs作为抗肿瘤免疫关键调节中心的双重性，即其既能促进免疫应答，也可能表现出抑制功能，并深入分析了其时空与功能异质性的分子机制。此文的突出价值在于整合了TLSs诱导、成熟及其与肿瘤微环境互作的最新研究进展，明确指出了其作为预后生物标志物和新型免疫治疗靶点的巨大转化潜力，为未来研究和临床应用提供了清晰的框架和方向。

---

## 7. 由hsa_circ_0065394编码的新型蛋白cPFKFB4在缺氧条件下通过增强PKM2介导的葡萄糖代谢重编程促进胰腺癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219790](https://pubmed.ncbi.nlm.nih.gov/41219790)
**期刊：** Molecular cancer
**PMID：** 41219790
**DOI：** 10.1186/s12943-025-02500-w

### 第一部分 原文与翻译

**英文原标题：** A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under hypoxia.

**英文摘要原文：**
BACKGROUND: Hypoxia is a hallmark of solid tumors and gives rise to the glucose metabolic reprogramming of cancers. Peptides and proteins encoded by circular RNAs (circRNAs) are identified as pivotal mediators in the malignant progression of tumors. Nonetheless, proteins encoded by hypoxia-related circRNAs in pancreatic cancer (PC) remain uncharacterized and poorly understood.

METHODS: Hypoxia-responsive circRNA (hsa_circ_0065394) in PC was screened using a hypoxic culture system. The circularization mechanism of hsa_circ_0065394 was investigated by employing bioinformatics and RNA immunoprecipitation. An assessment of the expression profile and potential clinical significance of hsa_circ_0065394 in PC was conducted utilizing qRT-PCR and in situ hybridization. Dual-luciferase reporter gene assay, mass spectrometry and western blotting identified a protein cPFKFB4 encoded by hsa_circ_0065394. The biological functions of cPFKFB4 were verified by gain- and loss-of-function experiments in vivo and in vitro. From a mechanistic standpoint, how cPFKFB4 modulates the interaction between hnRNP G and hnRNP A1 as well as the regulation of PKM alternative splicing was explored by conducting mass spectrometry, co-immunoprecipitation, immunofluorescence, PKM splicing, RNA immunoprecipitation, western blotting, and rescue experiments.

RESULTS: Hypoxia-associated hsa_circ_0065394 was noticeably up-regulated in PC tissues and tightly associated with tumor size. The biological cyclization of hsa_circ_0065394 was mediated by hnRNP L and Alu repeat sequences. Mechanistically, hsa_circ_0065394 encoded a 94 amino acid protein cPFKFB4 through a cap-independent mechanism. cPFKFB4 disrupted the hnRNP G-hnRNP A1 complex through specific binding to hnRNP G, facilitated hnRNP A1-mediated regulation of PKM alternative splicing, thereby heightening the expression of PKM2, and then strengthening glycolysis of PC cells to accelerate the proliferation and metastasis of PC under hypoxic conditions.

CONCLUSIONS: cPFKFB4, a protein encoded by hypoxia-responsive circular RNA, facilitates the proliferation and metastasis of PC cells under hypoxic conditions by regulating PKM2-mediated glycolysis. Our findings not only offer fresh standpoints and valuable insights into the crosstalk between hypoxia, glucose metabolism reprogramming, and PC, but also provide a potential biomarker and therapeutic target for the treatment of PC.

**中文摘要译文：**
背景：缺氧是实体瘤的一个标志，并引起肿瘤的葡萄糖代谢重编程。由环状RNA（circRNA）编码的多肽和蛋白质被认为是肿瘤恶性进展的关键介质。然而，在胰腺癌（PC）中由缺氧相关circRNA编码的蛋白质仍未被表征且知之甚少。

方法：使用缺氧培养体系筛选了胰腺癌中的缺氧响应性circRNA（hsa_circ_0065394）。通过生物信息学和RNA免疫沉淀研究了hsa_circ_0065394的环化机制。利用qRT-PCR和原位杂交评估了hsa_circ_0065394在胰腺癌中的表达谱和潜在临床意义。双荧光素酶报告基因检测、质谱分析和蛋白质印迹法鉴定出一种由hsa_circ_0065394编码的蛋白质cPFKFB4。通过体内和体外的功能增益和功能丧失实验验证了cPFKFB4的生物学功能。从机制角度，通过进行质谱分析、共免疫沉淀、免疫荧光、PKM剪接、RNA免疫沉淀、蛋白质印迹法和拯救实验，探究了cPFKFB4如何调节hnRNP G与hnRNP A1之间的相互作用以及对PKM选择性剪接的调控。

结果：缺氧相关的hsa_circ_0065394在胰腺癌组织中显著上调，并与肿瘤大小密切相关。hsa_circ_0065394的生物学环化由hnRNP L和Alu重复序列介导。机制上，hsa_circ_0065394通过一种帽非依赖性机制编码了一个由94个氨基酸组成的蛋白质cPFKFB4。cPFKFB4通过与hnRNP G特异性结合，破坏了hnRNP G-hnRNP A1复合物，促进了hnRNP A1介导的PKM选择性剪接调控，从而提高了PKM2的表达，并进而增强了胰腺癌细胞的糖酵解作用，以在缺氧条件下加速胰腺癌的增殖和转移。

结论：cPFKFB4，一种由缺氧响应性环状RNA编码的蛋白质，通过调节PKM2介导的糖酵解，在缺氧条件下促进胰腺癌细胞的增殖和转移。我们的研究结果不仅为缺氧、葡萄糖代谢重编程和胰腺癌之间的相互作用提供了新的视角和宝贵的见解，也为胰腺癌的治疗提供了一个潜在的生物标志物和治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示一种由缺氧响应性环状RNA（hsa_circ_0065394）编码的新型蛋白质在胰腺癌进展中的作用及分子机制。研究团队综合运用生物信息学、质谱分析及一系列体内外功能实验，发现该circRNA编码的cPFKFB4蛋白在缺氧条件下，通过与hnRNP G结合来调控PKM2的选择性剪接，进而增强糖酵解，最终促进了胰腺癌细胞的增殖与转移。该研究的创新之处在于首次报道了由circRNA编码的功能性蛋白在调控胰腺癌缺氧微环境与代谢重编程中的关键作用，不仅深化了对肿瘤进展机制的理解，也为胰腺癌的诊断和治疗提供了潜在的新靶点。

---

## 8. 用于哺乳动物基因组工程和分子记录的启动子及gRNA骨架元件清单

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219485](https://pubmed.ncbi.nlm.nih.gov/41219485)
**期刊：** Nature biotechnology
**PMID：** 41219485
**DOI：** 10.1038/s41587-025-02896-2

### 第一部分 原文与翻译

**英文原标题：** A parts list of promoters and gRNA scaffolds for mammalian genome engineering and molecular recording.

**英文摘要原文：**
A standardized 'parts list' of sequences for genetic engineering of microbes has been indispensable to progress in synthetic biology, but few analogous parts exist for mammalian systems. Here we design libraries of extant, ancestral, mutagenized or miniaturized variants of polymerase III promoters and guide RNA (gRNA) scaffolds and quantify their abilities to mediate precise edits to the mammalian genome through multiplex prime editing. We identify thousands of parts for reproducible editing in human and mouse cell lines, including hundreds with greater activity than commonly used sequences. Saturation mutagenesis screens identify tolerated sequence variants that further enhance sequence diversity. In an application to molecular recording, we design a 'ten key' array that, in mammalian cells, achieves balanced activity of pegRNAs as predicted by the activity of the component parts. The data reported here will aid the design of synthetic loci encoding arrays of gRNAs exhibiting predictable, differentiated levels of activity for applications in multiplexed perturbation, biological recorders and complex genetic circuits.

**中文摘要译文：**
用于微生物基因工程的标准化序列“元件清单”对合成生物学的进步至关重要，但适用于哺乳动物系统的类似元件却寥寥无几。本研究中，我们设计了聚合酶III启动子和导向RNA（gRNA）骨架的现存、祖先、诱变或微型化变体文库，并通过多重引导编辑技术量化了它们介导哺乳动物基因组精确编辑的能力。我们在人和小鼠细胞系中鉴定出数千个可实现可重复编辑的元件，其中包括数百个活性高于常用序列的元件。饱和突变筛选确定了可耐受的序列变体，这进一步增强了序列多样性。在一项分子记录应用中，我们设计了一个“十键”阵列，该阵列在哺乳动物细胞中实现了pegRNA的均衡活性，且其活性水平与组件元件的活性预测相符。本研究报道的数据将有助于设计编码gRNA阵列的合成基因座，这些阵列展现出可预测的、差异化的活性水平，适用于多重扰动、生物记录器和复杂遗传线路等应用。

### 第二部分 AI 大师评价

该研究旨在为哺乳动物系统建立一个标准化的基因工程“元件清单”，以解决合成生物学在这一领域的工具局限性。研究团队通过设计并测试大量启动子和gRNA骨架变体，利用多重引导编辑技术系统地评估了它们的编辑活性。其关键发现是鉴定出数千个高效且可预测的基因编辑元件，并成功应用于构建平衡的分子记录阵列，极大地丰富了哺乳动物基因工程的工具箱，为设计复杂的遗传线路和功能应用提供了坚实基础。

---

## 9. 多模态学习赋能单细胞数据的对话式探索

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219484](https://pubmed.ncbi.nlm.nih.gov/41219484)
**期刊：** Nature biotechnology
**PMID：** 41219484
**DOI：** 10.1038/s41587-025-02857-9

### 第一部分 原文与翻译

**英文原标题：** Multimodal learning enables chat-based exploration of single-cell data.

**英文摘要原文：**
Single-cell sequencing characterizes biological samples at unprecedented scale and detail, but data interpretation remains challenging. Here, we present CellWhisperer, an artificial intelligence (AI) model and software tool for chat-based interrogation of gene expression. We establish a multimodal embedding of transcriptomes and their textual annotations, using contrastive learning on 1 million RNA sequencing profiles with AI-curated descriptions. This embedding informs a large language model that answers user-provided questions about cells and genes in natural-language chats. We benchmark CellWhisperer's performance for zero-shot prediction of cell types and other biological annotations and demonstrate its use for biological discovery in a meta-analysis of human embryonic development. We integrate a CellWhisperer chat box with the CELLxGENE browser, allowing users to interactively explore gene expression through a combined graphical and chat interface. In summary, CellWhisperer leverages large community-scale data repositories to connect transcriptomes and text, thereby enabling interactive exploration of single-cell RNA-sequencing data with natural-language chats.

**中文摘要译文：**
单细胞测序以前所未有的规模和细节描绘了生物样本的特征，但数据解读仍然充满挑战。在此，我们介绍CellWhisperer，这是一款用于基因表达对话式查询的人工智能（AI）模型和软件工具。我们通过对100万个带有AI管理描述的RNA测序图谱进行对比学习，建立了转录组及其文本注释的多模态嵌入。这种嵌入技术为大语言模型提供了信息，使其能够在自然语言聊天中回答用户提出的关于细胞和基因的问题。我们对CellWhisperer在细胞类型及其他生物学注释的零样本预测性能进行了基准测试，并在人类胚胎发育的荟萃分析中展示了其在生物学发现中的应用。我们将CellWhisperer聊天框与CELLxGENE浏览器集成，允许用户通过图形与聊天相结合的界面进行基因表达的交互式探索。总之，CellWhisperer利用大型社区规模的数据库来连接转录组与文本，从而通过自然语言聊天的方式，实现了单细胞RNA测序数据的交互式探索。

### 第二部分 AI 大师评价

该研究旨在解决单细胞数据解读复杂性的挑战，为此开发了一款名为CellWhisperer的创新AI工具。其核心方法是利用多模态对比学习，将海量转录组数据与文本描述相关联，从而训练出一个能理解并回答生物学问题的大语言模型。这项工作的关键价值在于，它将复杂的生物信息学分析转变为直观的对话式探索，极大地降低了单细胞数据的使用门槛，使不具备高深编程技能的研究者也能轻松进行数据挖掘。CellWhisperer的出现，预示着未来生物数据分析将更加智能化和普及化，有望加速生物学领域的发现进程。

---

## 10. 通过工程化改造近端信号分子以增强CAR的敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219467](https://pubmed.ncbi.nlm.nih.gov/41219467)
**期刊：** Nature cancer
**PMID：** 41219467
**DOI：** 10.1038/s43018-025-01057-3

### 第一部分 原文与翻译

**英文原标题：** Enhancing CAR sensitivity through engineering of proximal signaling molecules.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究发表于顶尖期刊《自然-癌症》，旨在解决CAR-T细胞治疗中的关键瓶颈。其核心策略是通过对CAR结构中的近端信号分子进行工程化改造，以提高CAR对肿瘤抗原的敏感性。这项工作可能揭示了优化CAR激活阈值的特定分子设计，从而使免疫细胞能够更有效地识别和清除低抗原表达的癌细胞。此研究不仅为克服肿瘤免疫逃逸和治疗复发提供了新思路，也代表了CAR设计从“有无”到“精调”的下一代发展方向，具有重要的临床转化潜力。

---

## 11. 髓过氧化物酶：一酶双职。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219405](https://pubmed.ncbi.nlm.nih.gov/41219405)
**期刊：** Cell research
**PMID：** 41219405
**DOI：** 10.1038/s41422-025-01192-7

### 第一部分 原文与翻译

**英文原标题：** Myeloperoxidase: one enzyme, two jobs.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文标题精炼地揭示了其核心议题——髓过氧化物酶（MPO）的双重生物学功能。鉴于文献缺乏摘要，可推断这可能是一篇评述或观点性文章。文章或将深入探讨MPO在作为宿主防御关键武器（杀灭病原体）的同时，又如何作为一把“双刃剑”促进组织损伤和炎症反应，揭示其在不同生理及病理情境下的复杂角色，为相关疾病的治疗提供新的理论视角。

---

## 12. 剖析EGFR突变型非小细胞肺癌的EGFR TKI耐药机制与治疗策略演进

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219394](https://pubmed.ncbi.nlm.nih.gov/41219394)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41219394
**DOI：** 10.1038/s41571-025-01085-z

### 第一部分 原文与翻译

**英文原标题：** Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.

**英文摘要原文：**
Resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major obstacle in the clinical management of EGFR-mutant non-small-cell lung cancer (NSCLC). Despite the transformative therapeutic activity of the multiple iterations of EGFR TKIs, spanning from first-generation reversible inhibitors such as erlotinib and gefitinib to the current standard-of-care third-generation covalent inhibitor osimertinib, primary or acquired resistance to these agents inevitably emerges via diverse mechanisms. The advent of combination therapies that incorporate chemotherapy, anti-angiogenic agents, bispecific antibodies or antibody-drug conjugates has increased clinical benefit but introduced new resistance phenotypes, underscoring the dynamic plasticity and complexity of tumour evolution under therapeutic pressure. In this Review, we provide a comprehensive synthesis of the molecular mechanisms that underlie resistance to third-generation EGFR TKIs, describe biomarker-guided and biomarker-unselected therapeutic strategies to overcome these mechanisms, and discuss emerging approaches to pre-empt resistance through early application of combination therapies. We highlight the paradigm shift from radiological to molecular monitoring of resistance to therapy and explore how advances in circulating tumour DNA analysis, artificial intelligence and multi-omics might facilitate adaptive treatment strategies. As the therapeutic landscape evolves, a more complete mechanistic understanding of resistance will be essential to guide rational treatment sequencing, inform trial design and improve long-term outcomes for patients with EGFR-mutant NSCLC.

**中文摘要译文：**
在EGFR突变型非小细胞肺癌（NSCLC）的临床管理中，对EGFR酪氨酸激酶抑制剂（TKIs）的耐药仍然是一个主要障碍。尽管EGFR TKIs经历了多次迭代，从第一代可逆性抑制剂（如厄洛替尼和吉非替尼）到当前作为标准治疗的第三代共价抑制剂奥希替尼，展现出革命性的治疗活性，但针对这些药物的原发性或获得性耐药最终仍会通过多种不同机制出现。包含化疗、抗血管生成药物、双特异性抗体或抗体药物偶联物的联合疗法的出现，虽然增加了临床获益，但也引入了新的耐药表型，这凸显了肿瘤在治疗压力下演化的动态可塑性与复杂性。在这篇综述中，我们全面总结了第三代EGFR TKIs耐药的分子机制，描述了旨在克服这些机制的生物标志物指导和非选择性的治疗策略，并讨论了通过早期应用联合疗法来预先阻止耐药发生的新兴方法。我们重点阐述了从影像学监测转向分子学监测治疗耐药的范式转变，并探讨了循环肿瘤DNA分析、人工智能及多组学技术的进步如何促进适应性治疗策略的实施。随着治疗格局的不断演变，对耐药机制更全面的理解对于指导合理的治疗序列、为临床试验设计提供信息以及改善EGFR突变型NSCLC患者的长期预后至关重要。

### 第二部分 AI 大师评价

该综述全面系统地梳理了EGFR突变型非小细胞肺癌对第三代EGFR TKI（如奥希替尼）产生耐药的复杂分子机制。文章不仅总结了当前基于生物标志物的应对策略，更前瞻性地探讨了通过早期联合治疗预防耐药以及利用循环肿瘤DNA、人工智能等多组学技术进行动态监测的创新方法。本综述对临床医生制定个体化治疗序列和研究者设计新型临床试验具有重要的指导价值，深刻揭示了精准医学时代下抗击肿瘤耐药的未来发展方向。

---

## 13. Barrett食管与食管腺癌中异质性的生物学特性及其治疗意义

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219393](https://pubmed.ncbi.nlm.nih.gov/41219393)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41219393
**DOI：** 10.1038/s41571-025-01084-0

### 第一部分 原文与翻译

**英文原标题：** The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma.

**英文摘要原文：**
Oesophageal adenocarcinoma (OAC) and its precursor condition, Barrett oesophagus, are characterized by phenotypic and molecular intertumoural and intratumoural heterogeneity. This heterogeneity arises in space and time through a complex and still poorly understood interplay between cancer-cell-intrinsic factors, the tumour microenvironment and external influences, such as exposure to anticancer therapies. Together, these elements contribute to a high degree of resistance to therapy while limiting the development of novel targeted therapies and the identification of predictive biomarkers. This situation is exacerbated both in Barrett oesophagus and OAC by a historical clinical reliance on biopsy samples that reflect disease status only at a single location and timepoint. A better understanding of heterogeneity is therefore vital to improve efforts to intercept the development of and optimize treatments for OAC. In this Review, we provide an overview of current and future directions of research on the heterogeneity of Barrett oesophagus and OAC, summarizing our knowledge of the factors that influence heterogeneity, and its consequences across the spectrum of these diseases.

**中文摘要译文：**
食管腺癌（OAC）及其癌前病变Barrett食管的特点是表现出表型和分子层面的肿瘤间及肿瘤内异质性。这种异质性在空间和时间上通过癌细胞内在因素、肿瘤微环境以及抗癌治疗等外部影响之间复杂且尚不完全清楚的相互作用而产生。这些因素共同导致了高度的治疗抵抗，同时也限制了新型靶向疗法的开发和预测性生物标志物的识别。在Barrett食管和OAC中，由于临床上长期依赖于仅能反映单个位置和时间点疾病状态的活检样本，这种情况变得更加严峻。因此，更好地理解异质性对于改进拦截OAC发展的措施和优化治疗方案至关重要。在这篇综述中，我们概述了Barrett食管和OAC异质性研究的当前和未来方向，总结了我们对影响异质性的因素及其在这些疾病全谱中的后果的认识。

### 第二部分 AI 大师评价

该综述深刻阐述了Barrett食管及食管腺癌（OAC）的异质性问题，系统总结了其在表型和分子层面的时空复杂性。文章明确指出，这种由细胞内在因素、微环境与治疗共同驱动的异质性是导致治疗抵抗和新型疗法开发瓶颈的关键。通过批判性地审视传统单点活检的局限性，本综述强调了全面理解异质性对于优化OAC早期干预和治疗策略的至关重要的临床与科研价值，为未来的研究指明了方向。

---

## 14. Koina：实现蛋白质组学研究中机器学习的普及化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219230](https://pubmed.ncbi.nlm.nih.gov/41219230)
**期刊：** Nature communications
**PMID：** 41219230
**DOI：** 10.1038/s41467-025-64870-5

### 第一部分 原文与翻译

**英文原标题：** Koina: Democratizing machine learning for proteomics research.

**英文摘要原文：**
Recent developments in machine learning (ML) and deep learning have immense potential for applications in proteomics, such as generating spectral libraries, improving peptide identification, and optimizing targeted acquisition modes. Although new ML models are regularly published, the rate at which the community adopts these models is slow. This is in part due to a lack of findability and accessibility of these models as well as the technical challenges involved in incorporating these models into data analysis pipelines and demonstrating their reusability for end-users. Here we show Koina, an open-source decentralized and online-accessible model repository to facilitate publication of ML models. Koina enables ML model usage via an easy-to-use online interface, facilitating the integration of ML models in data analysis pipelines. Using the widely used FragPipe computational platform as an example, we demonstrate how Koina can be integrated with existing proteomics software tools and how these integrations improve data analysis.

**中文摘要译文：**
机器学习（ML）和深度学习的最新进展在蛋白质组学应用中展现出巨大潜力，例如生成谱图库、改进肽段鉴定和优化靶向采集模式。尽管新的机器学习模型不断发布，但学术界采纳这些模型的速度却很慢。这部分是由于这些模型缺乏可发现性和可及性，以及将它们整合到数据分析流程中并向最终用户展示其可重用性所涉及的技术挑战。在此，我们展示了 Koina，一个开源、去中心化且可在线访问的模型库，旨在促进机器学习模型的发布。Koina 通过一个易于使用的在线界面来实现机器学习模型的使用，从而简化了将模型集成到数据分析流程中的过程。我们以广泛使用的 FragPipe 计算平台为例，展示了 Koina 如何与现有的蛋白质组学软件工具集成，以及这种集成如何改善数据分析。

### 第二部分 AI 大师评价

本研究旨在解决先进的机器学习模型在蛋白质组学领域应用推广缓慢的核心难题。研究团队开发了一个名为 Koina 的开源、去中心化在线模型库，通过提供一个易于使用的界面，显著降低了研究人员集成和使用复杂模型的准入门槛。该研究通过与主流计算平台FragPipe的成功整合，证实了Koina能够有效促进模型共享与复用，提升数据分析效率。此项工作的创新价值在于为模型开发者与应用研究者之间搭建了一座关键桥梁，极大地推动了前沿算法在蛋白质组学科研中的普及化，对加速该领域的科学发现具有重要意义。

---

## 15. 一种抑制CD16a和CD16b脱落并促进抗肿瘤抗体依赖性细胞毒性作用的单克隆抗体

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219228](https://pubmed.ncbi.nlm.nih.gov/41219228)
**期刊：** Nature communications
**PMID：** 41219228
**DOI：** 10.1038/s41467-025-64862-5

### 第一部分 原文与翻译

**英文原标题：** A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors.

**英文摘要原文：**
CD16a triggers antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis by natural killer (NK) cells and macrophages in anti-tumor immunity. However, CD16a undergoes cleavage by ADAM17 that dampens its anti-tumor immunity. We here develop a monoclonal antibody (F9H4) that binds to CD16a and inhibits its cleavage. F9H4 retains CD16a on the surface of NK cells and macrophages, without triggering or blocking CD16a. F9H4 also binds to and inhibits shedding of CD16b by neutrophils, and inhibits CD16a/b shedding by leukocytes in tumor samples from lung cancer patients. F9H4 promotes ADCC against lung cancer cells that are opsonized by cetuximab, an epidermal growth factor receptor antibody that engages CD16a. F9H4 synergizes with cetuximab to inhibit human lung adenocarcinoma development in immunodeficient mice reconstituted with human NK cells. F9H4 combining with cetuximab also inhibits murine lung carcinoma growth in Fc gamma receptor-humanized mice, and such effect is mediated by NK cells and macrophages. The efficacy of F9H4+cetuximab in lung cancer models is the proof-of-concept for this new approach that promotes anti-tumor functions of Fc-enabled antibodies.

**中文摘要译文：**
在抗肿瘤免疫中，CD16a通过自然杀伤（NK）细胞和巨噬细胞触发抗体依赖性细胞介导的细胞毒性（ADCC）和吞噬作用。然而，CD16a会经历ADAM17的切割，这会削弱其抗肿瘤免疫力。我们在此研发了一种能与CD16a结合并抑制其切割的单克隆抗体（F9H4）。F9H4能将CD16a保留在NK细胞和巨噬细胞表面，而不会触发或阻断CD16a的功能。F9H4还能与中性粒细胞的CD16b结合并抑制其脱落，并能抑制肺癌患者肿瘤样本中白细胞的CD16a/b脱落。F9H4能促进针对经西妥昔单抗（一种与CD16a结合的表皮生长因子受体抗体）调理的肺癌细胞的ADCC作用。在重建了人NK细胞的免疫缺陷小鼠中，F9H4与西妥昔单抗协同作用，抑制人肺腺癌的进展。F9H4与西妥昔单抗联合使用，在Fcγ受体人源化小鼠中也能抑制鼠肺癌的生长，且此效应由NK细胞和巨噬细胞介导。F9H4联合西妥昔单抗在肺癌模型中的疗效，为这种旨在增强Fc功能抗体抗肿瘤作用的新策略提供了概念验证。

### 第二部分 AI 大师评价

本研究旨在解决抗肿瘤免疫中关键受体CD16a因切割脱落而导致功能减弱的问题。研究团队成功开发了一种新型单克隆抗体F9H4，它能特异性抑制CD16a/b的脱落，从而稳定其在NK细胞和巨噬细胞表面的表达。关键发现表明，F9H4与西妥昔单抗等现有治疗性抗体联用，能显著增强抗体依赖的细胞毒性（ADCC）效应，并在肺癌动物模型中展现出强大的协同抗肿瘤活性。此项研究为提升Fc功能抗体的疗效提供了一种创新的增效策略，具有重要的临床转化潜力，有望改善现有抗体药物的治疗效果。

---

## 16. 癌症恶液质的新视角：迷走神经脑-肝轴作为一个新型神经代谢靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219223](https://pubmed.ncbi.nlm.nih.gov/41219223)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41219223
**DOI：** 10.1038/s41392-025-02483-6

### 第一部分 原文与翻译

**英文原标题：** Reframing cancer cachexia: the vagal brain-liver axis as a novel neuro-metabolic target.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题提出了一种关于癌症恶液质的创新性观点，旨在将研究视角从传统的代谢紊乱转向神经-代谢调控。文章的核心假说可能聚焦于“迷走神经脑-肝轴”在恶液质病理生理过程中的关键作用，并探讨其作为潜在治疗新靶点的可行性。这一神经内分泌与代谢相结合的视角极具前瞻性，为开发针对恶液质的全新干预策略（如神经调控或靶向肝脏代谢）提供了重要的理论框架和研究方向。由于缺乏摘要，本文的具体研究内容和实验证据尚不明确。

---

## 17. 工程化表达CXCR3-A可增强靶向B7-H3的CAR-T细胞迁移能力及其对弥漫性内生性脑桥胶质瘤的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219209](https://pubmed.ncbi.nlm.nih.gov/41219209)
**期刊：** Nature communications
**PMID：** 41219209
**DOI：** 10.1038/s41467-025-64861-6

### 第一部分 原文与翻译

**英文原标题：** Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma.

**英文摘要原文：**
Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. Chimeric antigen receptor (CAR) T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our recent clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, here we aim to leverage this CXCL10 upregulation to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. We demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.

**中文摘要译文：**
弥漫性内生性脑桥胶质瘤（DIPG）是一种致命的脑干肿瘤，迫切需要更有效的治疗方法。用于治疗DIPG的嵌合抗原受体（CAR）T细胞疗法已显示出临床耐受性和生物活性，但并未实现普遍获益。一个主要障碍是CAR-T细胞向肿瘤组织的迁移不足。鉴于我们近期的临床试验证明了趋化因子受体CXCR3的配体CXCL10在局部区域的升高，本研究旨在通过改造靶向B7-H3的CAR-T细胞以过表达CXCR3变体，从而利用CXCL10的上调来增强细胞迁移。我们证明，与未经修饰的B7-H3 CAR-T细胞相比，经CXCR3-A修饰的CAR-T细胞在体外能更有效地向CXCR3配体迁移；并且，在原位DIPG小鼠模型中通过脑室内递送时，经CXCR3-A修饰的CAR-T细胞表现出更强的肿瘤内迁移能力和更优的治疗效果。总而言之，我们的数据支持通过工程化表达CXCR3-A来增强CAR-T细胞对DIPG的迁移能力和疗效的潜力。

### 第二部分 AI 大师评价

本研究旨在解决CAR-T细胞治疗实体瘤（尤其是DIPG）时面临的关键瓶颈——肿瘤迁移和浸润不足。研究团队巧妙地利用DIPG肿瘤微环境中CXCL10高表达的特性，通过工程化改造使靶向B7-H3的CAR-T细胞表达其受体CXCR3-A，相当于为CAR-T细胞安装了“导航系统”。关键发现证实，这种改造显著增强了CAR-T细胞向肿瘤的迁移能力，并在动物模型中展现出更优的治疗效果。该策略具有高度的创新性和临床转化潜力，为优化实体瘤的CAR-T细胞疗法提供了重要的新思路。

---

## 18. 利用冷冻电镜和计算建模对pH调节因子NBCn1的结构解析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219199](https://pubmed.ncbi.nlm.nih.gov/41219199)
**期刊：** Nature communications
**PMID：** 41219199
**DOI：** 10.1038/s41467-025-64868-z

### 第一部分 原文与翻译

**英文原标题：** CryoEM and computational modeling structural insights into the pH regulator NBCn1.

**英文摘要原文：**
Breast cancer cells survive despite being exposed to a toxic acidic extracellular environment, by utilizing the NBCn1 transporter. The molecular basis for this phenomenon is unknown, given the lack of an NBCn1 atomic structural model. We therefore determined the 3.3 Å cryoEM structure of the human NBCn1 outward facing (OF) conformational state with densities corresponding to the transported ions in the ion coordination site. We further generated NBCn1 inward facing (IF) and intermediate (occluded) structures and characterized the transport cycle and the ion dynamics in the IF and OF states. The results showed that NBCn1 utilizes an elevator-type transport mechanism with a small vertical shift of the ion coordination site between OF and IF conformational states and that the transported ions permeate without significant energy barriers. Functional experiments showed that NBCn1 has an extremely high ion turnover rate (TOR) of ~15,000 s. The unusually high NBCn1 TOR value associated with the small protein structural changes during the OF to IF transitions and the favorable ion permeation energetics provides breast cancer cells with a highly efficient base loading mechanism contributing to their survival advantage.

**中文摘要译文：**
乳腺癌细胞通过利用NBCn1转运蛋白，得以在有毒的酸性细胞外环境中生存。由于缺乏NBCn1的原子结构模型，这一现象的分子基础尚不清楚。因此，我们解析了人源NBCn1处于外向开放（OF）构象状态的3.3 Å冷冻电镜结构，并观察到与离子配位点中被转运离子相对应的密度图。我们进一步生成了NBCn1的内向开放（IF）和中间（闭塞）状态的结构，并描述了其转运周期以及在IF和OF状态下的离子动力学。结果表明，NBCn1采用一种电梯式转运机制，其OF和IF构象状态之间的离子配位点仅发生微小的垂直位移，并且所转运的离子能够无显著能量壁垒地通过。功能性实验显示，NBCn1具有极高的离子转换率（TOR），约为15,000/秒。NBCn1异常高的离子转换率，加上其在OF到IF转变过程中微小的蛋白质结构变化以及有利的离子渗透能垒，共同为乳腺癌细胞提供了一种高效的碱装载机制，从而有助于其获得生存优势。

### 第二部分 AI 大师评价

本研究通过结合冷冻电镜技术与计算建模，首次解析了人源pH调节因子NBCn1的高分辨率三维结构。研究揭示了NBCn1采用一种高效的“电梯式”转运机制，其构象变化小、离子渗透能垒低，从而实现了极高的离子转运速率。这一发现不仅从分子层面阐明了乳腺癌细胞适应酸性微环境的关键机制，也为开发靶向NBCn1的新型抗癌药物提供了精确的结构基础，具有重要的科研与临床转化价值。

---

## 19. 野生型KRAS激活驱动肝细胞癌中干扰素介导的免疫逃逸及对免疫疗法的耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219194](https://pubmed.ncbi.nlm.nih.gov/41219194)
**期刊：** Nature communications
**PMID：** 41219194
**DOI：** 10.1038/s41467-025-64860-7

### 第一部分 原文与翻译

**英文原标题：** Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma.

**英文摘要原文：**
Increasing evidence indicates that activation of oncogenic pathways contributes to an unfavourable tumour immune microenvironment (TIME), ultimately resulting in resistance to immunotherapy. Here, we aim to identify a critical oncogenic pathway involved in an antigen-expressing c-MYC-lucOS/Tp53 hepatocellular carcinoma (HCC) mouse model that simulates immune response against tumour-associated antigens. Using data-independent acquisition proteomics, we reveal the role of wild-type KRAS in immune escaped mouse HCC tumours, with EGF concurrently activating EGFR/MEK/ERK signalling. Single cell RNA sequencing data analysis reveals that KRAS signalling intrinsically inhibits interferon-mediated MHC-I expression and extrinsically impairs CD8 T cell activity due to the suppression of CXCL9 through the EGFR/MEK/ERK pathway. We observe KRAS activation in HCC patients who received immune checkpoint inhibitor (ICI) treatments, where it correlates with poor clinical outcomes. Notably, combination therapy with SOS1 inhibitor MRTX0902, Trametinib, and anti-PD-1 antibody effectively increased intratumoural CD8 T cell infiltration and improved survival. Our study thus reveals that targeting wild-type KRAS signalling in combination with ICIs may serve as an effective treatment strategy for advanced HCC patients.

**中文摘要译文：**
越来越多的证据表明，致癌通路的激活会导致不利的肿瘤免疫微环境（TIME），最终导致对免疫疗法的耐药。在本研究中，我们旨在一种表达抗原的c-MYC-lucOS/Tp53肝细胞癌（HCC）小鼠模型中，鉴定出一个关键的致癌通路，该模型可模拟针对肿瘤相关抗原的免疫反应。通过使用数据非依赖性采集蛋白质组学，我们揭示了野生型KRAS在免疫逃逸的HCC小鼠肿瘤中的作用，同时表皮生长因子（EGF）激活了EGFR/MEK/ERK信号通路。单细胞RNA测序数据分析显示，KRAS信号通路通过EGFR/MEK/ERK途径抑制CXCL9，从而内在性地抑制干扰素介导的MHC-I表达，并外在性地损害CD8 T细胞活性。我们观察到，在接受免疫检查点抑制剂（ICI）治疗的HCC患者中存在KRAS激活，且这种激活与不良的临床结局相关。值得注意的是，SOS1抑制剂MRTX0902、曲美替尼和抗PD-1抗体的联合治疗，能有效增加肿瘤内CD8 T细胞的浸润并提高生存率。因此，我们的研究揭示，将靶向野生型KRAS信号通路与ICI相结合，可能成为晚期HCC患者的一种有效治疗策略。

### 第二部分 AI 大师评价

该研究旨在揭示野生型KRAS激活在肝细胞癌（HCC）免疫逃逸及免疫治疗耐药中的关键作用。研究团队综合运用了蛋白质组学和单细胞测序等前沿技术，在小鼠模型和临床样本中发现，KRAS通过EGFR/MEK/ERK通路抑制干扰素信号及CXCL9表达，从而削弱了抗肿瘤免疫。这项研究的创新之处在于阐明了非突变型KRAS在HCC免疫抑制中的新机制，并验证了靶向KRAS信号通路联合免疫检查点抑制剂的协同抗癌效果，为改善晚期HCC患者的治疗策略提供了坚实的实验依据和转化潜力。

---

## 20. 靶向多胺代谢和铁死亡可增强KRAS靶向治疗的疗效，且该疗效依赖于KEAP1状态

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41219185](https://pubmed.ncbi.nlm.nih.gov/41219185)
**期刊：** Nature communications
**PMID：** 41219185
**DOI：** 10.1038/s41467-025-65441-4

### 第一部分 原文与翻译

**英文原标题：** Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status.

**英文摘要原文：**
The resistance to KRAS-targeted therapies, particularly due to co-occurring gene mutations, remains a significant challenge. Through a metabolite library screening, we reveal that polyamines sensitize KRAS inhibitors only in KRAS/KEAP1 cells but not in KRAS/KEAP1 cells. Transcriptome sequencing and metabolome profiling pinpoint SAT1, the key enzyme in polyamine metabolism, as essential for this divergence. In KRAS/KEAP1 context, treatment of KRAS inhibitors activates JNK/c-Jun pathway and SAT1 expression, while the augmented SAT1 facilitates polyamine metabolism and KRAS inhibitors-induced ferroptosis. Conversely, in KRAS/KEAP1 cells, activated JNK promotes the degradation of NRF2, thereby inhibiting SAT1 expression. Our results further demonstrate that polyamine supplementation enhances KRAS-targeted therapy in KRAS/KEAP1 resistant cells, patient-derived organoids, xenografts, and spontaneously tumorigenic mice, while KRAS/KEAP1 models require lentivirus or adeno-associated virus-mediated SAT1 overexpression prior to polyamine treatment, to augment ferroptosis and drug sensitivity. Our findings highlight SAT1-mediated polyamine metabolism as a promising target in precision treatments for KRAS-mutant cancers.

**中文摘要译文：**
对KRAS靶向治疗的耐药，特别是由于基因共突变引起的耐药，仍然是一个重大挑战。通过代谢物库筛选，我们发现多胺仅在KRAS/KEAP1[突变型]细胞中能增强KRAS抑制剂的敏感性，而在KRAS/KEAP1[野生型]细胞中则无效。转录组测序和代谢组分析明确指出，多胺代谢的关键酶SAT1是造成这种差异的根本原因。在KRAS/KEAP1[突变型]背景下，KRAS抑制剂治疗可激活JNK/c-Jun通路和SAT1的表达，而增加的SAT1则促进多胺代谢及KRAS抑制剂诱导的铁死亡。相反，在KRAS/KEAP1[野生型]细胞中，被激活的JNK会促进NRF2的降解，从而抑制SAT1的表达。我们的研究结果进一步表明，补充多胺可增强KRAS靶向治疗在KRAS/KEAP1[突变型]耐药细胞、患者来源的类器官、异种移植物和自发性肿瘤小鼠模型中的疗效；而KRAS/KEAP1[野生型]模型则需要在多胺治疗前，通过慢病毒或腺相关病毒介导的SAT1过表达来增强铁死亡和药物敏感性。我们的研究结果凸显了SAT1介导的多胺代谢是KRAS突变型癌症精准治疗中一个有前景的靶点。

### 第二部分 AI 大师评价

本研究旨在探索靶向多胺代谢与铁死亡以增强KRAS靶向治疗效果的策略，并阐明其作用机制与KEAP1突变状态的相关性。研究通过代谢物筛选、多组学分析及多种体内外模型，关键性地发现多胺仅在KEAP1突变的KRAS肿瘤中，通过上调SAT1表达来诱导铁死亡，从而对KRAS抑制剂增敏。该研究创新性地揭示了“多胺-SAT1-铁死亡”轴在决定KRAS靶向治疗疗效中的核心作用，为根据KEAP1基因型制定精准联合治疗方案提供了坚实的理论基础和新的临床转化方向。

---

## 21. 描绘B细胞与三级淋巴结构的免疫图景，揭示其在神经母细胞瘤中的临床影响。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41218854](https://pubmed.ncbi.nlm.nih.gov/41218854)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41218854
**DOI：** 10.1136/jitc-2025-012860

### 第一部分 原文与翻译

**英文原标题：** Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.

**英文摘要原文：**
BACKGROUND: Immunotherapy has transformed cancer treatment, highlighting the importance of effective antitumor immunity to fight cancer. However, its success in pediatric cancer remains limited, underscoring the urgent need to identify new immunotherapeutic targets. In this study, we explored the clinical relevance of B cells and tertiary lymphoid structures (TLS) in neuroblastoma (NB), a pediatric tumor with a heterogeneous immune landscape.

METHODS: We analyzed 87 treatment-naïve NB specimens, spanning both localized and metastatic disease previously characterized for T-cell and dendritic cell (DC) infiltration. B cells were detected by immunohistochemistry, and plasma cells were quantified using multiple immunofluorescence. Spatial organization and functional status of immune cells within TLSs were assessed by imaging mass cytometry using a 29-antibody panel. In parallel, gene expression profiles were obtained through NanoString PanCancer Immune Profiling and further validated using publicly available bulk and single-cell RNA-sequencing data from untreated and treated NB samples. These transcriptomic datasets were used to support protein-level findings and to identify prognostic gene signatures.

RESULTS: B-cell infiltration in NB tumors strongly correlated with the presence of T cells and DCs at both protein and transcriptomic levels, and was associated with improved prognosis. Similar to other solid tumors, B cells in NB were either scattered throughout the tumor or organized into TLSs of varying maturity. Spatial proteomic and transcriptomic analyses revealed that localized tumors often contain mature TLSs, with functional B cells able to antigen presentation and immunoglobulin expression, alongside high cytotoxic T cells. In contrast, metastatic tumors primarily exhibited immature TLSs, with evidence of B-cell and T-cell dysfunction. Importantly, we identified gene signatures associated with B cells and TLSs that not only predicted survival in NB but were also prognostic in multiple adult cancers.

CONCLUSIONS: Our findings highlight a central role for B cells and TLSs in shaping the immune microenvironment of NB. Their presence and maturation status are linked to clinical outcome, suggesting their potential as prognostic biomarkers and targets for novel immunotherapeutic strategies in pediatric oncology.

**中文摘要译文：**
背景：免疫疗法已经改变了癌症治疗，凸显了有效抗肿瘤免疫在抗击癌症中的重要性。然而，其在儿童癌症中的成功仍然有限，这突出表明迫切需要确定新的免疫治疗靶点。在本研究中，我们探讨了B细胞和三级淋巴结构（TLS）在神经母细胞瘤（NB）中的临床相关性，这是一种具有异质性免疫图景的儿童肿瘤。

方法：我们分析了87份未经治疗的NB标本，涵盖了局限性及转移性疾病，这些标本先前已对其T细胞和树突状细胞（DC）的浸润情况进行了表征。通过免疫组织化学法检测B细胞，并使用多重免疫荧光法对浆细胞进行定量。采用包含29种抗体的抗体组合，通过成像质谱流式细胞术评估了TLS内免疫细胞的空间组织和功能状态。同时，通过NanoString PanCancer免疫分析平台获得基因表达谱，并利用来自未经治疗和经过治疗的NB样本的公共批量及单细胞RNA测序数据进行进一步验证。这些转录组数据集被用于支持蛋白质水平的发现，并识别预后相关的基因特征。

结果：在蛋白质和转录组水平上，NB肿瘤中的B细胞浸润与T细胞和DC的存在密切相关，并与改善的预后相关联。与其他实体瘤相似，NB中的B细胞或散布于整个肿瘤中，或组织成不同成熟度的TLS。空间蛋白质组学和转录组学分析显示，局限性肿瘤通常含有成熟的TLS，其中功能性B细胞能够进行抗原呈递和免疫球蛋白表达，并伴有高水平的细胞毒性T细胞。相比之下，转移性肿瘤主要表现为不成熟的TLS，并有B细胞和T细胞功能障碍的证据。重要的是，我们鉴定出与B细胞和TLS相关的基因特征，这些特征不仅能预测NB的生存期，而且在多种成人癌症中也具有预后价值。

结论：我们的研究结果突显了B细胞和TLS在塑造NB免疫微环境中的核心作用。它们的存在与成熟状态与临床结局相关，表明它们有潜力成为儿童肿瘤学中新的预后生物标志物和免疫治疗策略的靶点。

### 第二部分 AI 大师评价

本研究创新性地运用多组学方法，深入剖析了B细胞及三级淋巴结构（TLS）在神经母细胞瘤中的作用。通过结合先进的成像质谱流式细胞术与转录组学分析，研究不仅揭示了B细胞浸润和TLS成熟度是影响预后的关键因素，还区分了局限性与转移性肿瘤中免疫微环境的显著差异。此项工作将TLS的成熟状态确立为儿童肿瘤中一个极具潜力的预后生物标志物和新的免疫治疗靶点，为改善儿童癌症的治疗策略提供了重要依据和新方向。

---

## 22. 全身性mRNA疫苗在犬脑肿瘤中引发快速的免疫激活。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41218853](https://pubmed.ncbi.nlm.nih.gov/41218853)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41218853
**DOI：** 10.1136/jitc-2025-011817

### 第一部分 原文与翻译

**英文原标题：** Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors.

**英文摘要原文：**
Malignant glioma is considered invariably recalcitrant, thus necessitating development of new therapeutic approaches. Spontaneously arising canine glioma exhibits important molecular and pathological similarities to malignant pediatric glioma, making it an invaluable model for testing novel therapies. We evaluated safety and activity of RNA lipid particle aggregates (LPAs) designed to provoke cancer immunogenicity in 10 dogs with histologically confirmed glioma. Vaccine manufacturing was feasible in all subjects and generally well tolerated. Median survival time was 123 and 155 days in dogs receiving three (Group A) or four (Group B) vaccines, respectively; this was increased from historical reporting of subjects receiving palliative care. Responding animals had a robust cytokine response following infusions. In animals receiving non-specific RNA-LPAs, there was localization of messenger RNA (mRNA) payloads to the brain tumor microenvironment and a rapid shift in immunologic gene signatures consistent with a viral response. These data demonstrate the ability to induce rapid viremic response in the tumor microenvironment following a single peripherally administered mRNA vaccine. Since RNA-LPAs are amenable to repeat boosts, these formulations may overcome challenges of tumor immunosuppression and therapeutic access and are currently under evaluation in first-in-human trials (NCT04573140, NCT06389591).

**中文摘要译文：**
恶性胶质瘤被认为是始终难以治愈的，因此有必要开发新的治疗方法。自发性犬胶质瘤在分子和病理学上与恶性儿童胶质瘤表现出重要的相似性，使其成为测试新疗法的宝贵模型。我们评估了旨在激发癌症免疫原性的RNA脂质颗粒聚集体（LPAs）在10只经组织学确诊的胶质瘤犬中的安全性和活性。所有受试对象的疫苗制造均可行，且普遍耐受良好。接受三次（A组）或四次（B组）疫苗的犬只中位生存时间分别为123天和155天；这比接受姑息治疗的历史报告对象的生存时间有所增加。有应答的动物在输注后表现出强烈的细胞因子反应。在接受非特异性RNA-LPAs的动物中，信使RNA（mRNA）有效载荷定位于脑肿瘤微环境，并观察到免疫学基因特征迅速转变为与病毒反应一致的模式。这些数据表明，单次外周施用mRNA疫苗后，能够在肿瘤微环境中诱导快速的病毒血症样反应。由于RNA-LPAs适用于重复加强免疫，这些制剂可能克服肿瘤免疫抑制和治疗可及性的挑战，并且目前正在首次人体试验（NCT04573140, NCT06389591）中进行评估。

### 第二部分 AI 大师评价

本研究旨在评估全身性mRNA疫苗在治疗犬脑胶质瘤中的安全性与初步疗效。研究通过对10只患病犬施用RNA脂质颗粒聚集体（LPA）疫苗，发现该疗法不仅耐受性良好，延长了中位生存期，更关键的是能在外周给药后迅速在脑肿瘤微环境中诱导强烈的、类似病毒感染的免疫反应。这项研究的创新之处在于验证了全身性mRNA疫苗能够有效激活中枢神经系统肿瘤的局部免疫，为治疗恶性胶质瘤这一“冷”肿瘤提供了极具前景的新策略，并为正在进行的人体临床试验奠定了坚实的转化医学基础。

---

## 23. 造血系统TET2失活可增强免疫检查点阻断疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41218172](https://pubmed.ncbi.nlm.nih.gov/41218172)
**期刊：** Cancer research
**PMID：** 41218172
**DOI：** 10.1158/0008-5472.CAN-24-3329

### 第一部分 原文与翻译

**英文原标题：** Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 Inactivation.

**英文摘要原文：**
Somatic mutations inactivating TET2 are among the most common drivers of clonal hematopoiesis (CH). TET2 inactivation is associated with monocyte-derived inflammation and improved chimeric antigen receptor T cell function, suggesting it might also impact immunotherapy response. Here, we found that hematopoietic Tet2 mutation in mouse models enhanced the immune checkpoint blockade (ICB) response, which required the combined presence of phagocytes, CD4+, and CD8+ T cells. The effect was lost with myeloid- or T-cell restricted Tet2 inactivation or in mice with 20% Tet2-mutant hematopoiesis. Mechanistically, in Tet2-mutant tumor-infiltrating leukocytes (TILs), ICB preferentially restricted cell states linked to tumor progression while inducing anti-tumor states. Tet2-mutant monocytes activated costimulatory programs, while Tet2-mutant T cells showed enhanced T cell memory signatures, alongside decreased exhaustion and regulatory phenotypes. Clinically, tumors from colorectal cancer and melanoma patients with TET2 driver mutation-CH (TET2-CH) showed enhanced immune infiltration, inflammation, and T cell activation. In melanoma patients treated with ICB, TET2-CH was associated with 6-fold greater odds of clinical benefit. Collectively, this work demonstrates that hematopoietic TET2 inactivation primes leukocytes for anti-tumor states associated with immunotherapy response and provides a potential biomarker for personalized therapy.

**中文摘要译文：**
导致TET2失活的体细胞突变是克隆性造血（CH）最常见的驱动因素之一。TET2失活与单核细胞源性炎症及嵌合抗原受体T细胞功能改善相关，这提示它也可能影响免疫治疗应答。本研究中，我们发现小鼠模型中的造血系统Tet2突变可增强免疫检查点阻断（ICB）的应答，该效应需要吞噬细胞、CD4+和CD8+ T细胞的共同存在。在髓系或T细胞限制性Tet2失活，或在Tet2突变造血比例为20%的小鼠中，该效应消失。从机制上讲，在Tet2突变的肿瘤浸润白细胞（TILs）中，ICB优先抑制与肿瘤进展相关的细胞状态，同时诱导抗肿瘤状态。Tet2突变的单核细胞激活了共刺激程序，而Tet2突变的T细胞则表现出增强的T细胞记忆特征，同时耗竭和调节性表型减少。临床上，伴有TET2驱动突变克隆性造血（TET2-CH）的结直肠癌和黑色素瘤患者的肿瘤表现出增强的免疫浸润、炎症和T细胞活化。在接受ICB治疗的黑色素瘤患者中，TET2-CH与临床获益几率增加6倍相关。总而言之，这项工作表明造血系统TET2失活能使白细胞进入与免疫治疗应答相关的抗肿瘤状态，并为个体化治疗提供了一个潜在的生物标志物。

### 第二部分 AI 大师评价

本研究旨在探究常见的克隆性造血驱动突变——TET2失活，对免疫检查点阻断（ICB）疗效的影响。研究综合运用小鼠模型和临床数据分析，发现造血系统TET2失活能显著增强ICB的抗肿瘤应答。其核心机制在于，TET2失活可促使单核细胞和T细胞等免疫细胞进入更具活性的抗肿瘤状态，从而重塑了肿瘤免疫微环境。该研究不仅揭示了宿主遗传背景影响免疫治疗的重要机制，更重要的是，它提出TET2-CH可作为一个极具潜力的预测性生物标志物，为筛选ICB优势人群和指导个体化治疗提供了重要依据。

---

## 24. 四跨膜蛋白13通过促进MHC-I类分子降解来增强乳腺癌的免疫逃逸

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41218148](https://pubmed.ncbi.nlm.nih.gov/41218148)
**期刊：** Cancer research
**PMID：** 41218148
**DOI：** 10.1158/0008-5472.CAN-25-1223

### 第一部分 原文与翻译

**英文原标题：** Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation.

**英文摘要原文：**
In contrast to highly immunogenic malignancies, breast cancer frequently features a "cold" tumor immune microenvironment marked by low immune cell infiltration and limited activation of effector T cells. This immunosuppressive phenotype poses a substantial barrier to the efficacy of immune checkpoint inhibitors and other immunotherapeutic approaches, highlighting the need to identify mechanisms limiting antitumor immunity. In this study, we identified a role for tetraspanin 13 (TSPAN13) in regulating major histocompatibility complex class I (MHC-I) expression on the surface of tumor cells, which is required for the recognition of tumor-specific antigens by CD8+ T cells. In breast cancer patient samples, TSPAN13 expression negatively correlated with CD8⁺ T cell infiltration. Mechanistically, TSPAN13 enhanced the ubiquitination of MHC-I by recruiting STUB1, thereby promoting lysosomal degradation and significantly reducing MHC-I levels on the cell surface. Both in vitro and in vivo experiments demonstrated that loss of TSPAN13 in tumor cells significantly enhanced CD8+ T cell activity and improved cytotoxicity against tumor cells. Moreover, suppression of TSPAN13 expression significantly increased tumor sensitivity to anti-PD-L1 therapy. Together, these findings suggest that TSPAN13 is a potential therapeutic target for breast cancer immunotherapy.

**中文摘要译文：**
与高免疫原性恶性肿瘤相比，乳腺癌通常表现为“冷”肿瘤免疫微环境，其特征是免疫细胞浸润水平低和效应T细胞活化受限。这种免疫抑制表型对免疫检查点抑制剂和其他免疫治疗方法的疗效构成了巨大障碍，凸显了识别限制抗肿瘤免疫机制的必要性。本研究发现，四跨膜蛋白13（TSPAN13）在调节肿瘤细胞表面的主要组织相容性复合体I类分子（MHC-I）表达中发挥作用，而MHC-I是CD8+ T细胞识别肿瘤特异性抗原所必需的。在乳腺癌患者样本中，TSPAN13的表达与CD8⁺ T细胞的浸润呈负相关。从机制上看，TSPAN13通过招募STUB1来增强MHC-I的泛素化，从而促进其溶酶体降解，并显著降低细胞表面的MHC-I水平。体外和体内实验均表明，肿瘤细胞中TSPAN13的缺失能显著增强CD8+ T细胞的活性，并提高其对肿瘤细胞的细胞毒性作用。此外，抑制TSPAN13的表达能显著提高肿瘤对抗PD-L1疗法的敏感性。综上所述，这些发现表明TSPAN13是乳腺癌免疫治疗的一个潜在治疗靶点。

### 第二部分 AI 大师评价

该研究旨在揭示四跨膜蛋白13（TSPAN13）在乳腺癌免疫逃逸中的作用及机制。研究通过分析患者样本、分子机制探究以及体内外功能实验，发现TSPAN13能通过招募STUB1蛋白促进MHC-I分子的泛素化与降解，从而下调肿瘤细胞的抗原提呈能力，导致免疫逃逸。这项研究的创新之处在于阐明了TSPAN13作为将乳腺癌转变为“冷”肿瘤的关键分子，并证实抑制TSPAN13可增强抗PD-L1疗法的效果，为改善乳腺癌免疫治疗提供了极具潜力的药物靶点和新的联合治疗策略。

---

速递结束，祝您工作愉快！